BRIEF—Bioasis contracts WuXi to develop brain cancer candidate

Bioasis Technologies and WuXi Biologics have agreed a strategic collaboration for the development and manufacturing of xB3-001, Bioasis’ lead investigational biological candidate to treat brain cancer.

Bioasis has a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders.

The firm’s chief executive Mark Day said, “WuXi Biologics’ expertise and experience in manufacturing biologics is instrumental to Bioasis in developing our pipeline.”